Art

J-GLOBAL ID：201102254665583092   Reference number：11A0984137

Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia

血漿濃度に基づいた用量調整よりもイマチニブの標準用量を遵守することが,慢性骨髄性白血病患者の深い分子応答の達成には重要である

Author (19)： YOSHIDA Chikashi (Mito Medical Center, Higashiibarakigun, JPN) ,  KOMENO Takuya (Mito Medical Center, Higashiibarakigun, JPN) ,  HORI Mitsuo (Ibaraki Prefectural Central Hospital, Kasama, JPN) ,  KIMURA Tomofumi (Suifu Hospital, Mito, JPN) ,  FUJII Masami (Suifu Hospital, Mito, JPN) ,  OKOSHI Yasushi (Univ. Tsukuba, Tsukuba, JPN) ,  SUZUKAWA Kazumi (Univ. Tsukuba, Tsukuba, JPN) ,  CHIBA Shigeru (Univ. Tsukuba, Tsukuba, JPN) ,  HASEGAWA Yuichi (Univ. Tsukuba, Tsukuba, JPN) ,  YAMAMOTO MUKAI Harumi (Univ. Tsukuba, Tsukuba, JPN) ,  ITO Takayoshi (Toride Kyodo General Hospital, Toride, JPN) ,  SHIMIZU Seiichi (Tsuchiura Kyodo General Hospital, Tsuchiura, JPN) ,  KAMOSHITA Masaharu (Tsuchiura Kyodo General Hospital, Tsuchiura, JPN) ,  KUDO Daisuke (Hitachi General Hospital, Hitachi, JPN) ,  SHINAGAWA Atsushi (Hitachi General Hospital, Hitachi, JPN) ,  CHIKATSU Norio (Hitachi General Hospital, Hitachi, JPN) ,  MONMA Yuriko (Hitachi General Hospital, Hitachi, JPN) ,  WATANABE Norimichi (Watanabe Naika Clinic, Hitachinaka, JPN) ,  KOJIMA Hiroshi (Ibaraki Prefectural Central Hospital, Ibaraki, JPN)
Material： International Journal of Hematology  (Int J Hematol)
Volume： 93  Issue： 5  Page： 618-623  Publication year： May. 2011 
JST Material Number： F0888A  ISSN： 0925-5710  CODEN： IJHEEY  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： 分子応答 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=11A0984137&from=J-GLOBAL&jstjournalNo=F0888A") }}

JST classification (3)： Blood cell tumors(=neoplasms)  (GK04000M) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Substance index (1)： Imatinib

Reference (20)：

• GOLDMAN, JM. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med. 2003, 349, 1451-1464
• HOCHHAUS, A. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009, 23, 1054-1061
• DEININGER, M. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up : Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. ASH Annual Meeting Abstracts. 2009, 114, 1126
• GORRE, ME. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001, 293, 876-880
• NOENS, L. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia : the ADAGIO study. Blood. 2009, 113, 5401-5411

Terms in the title (9)： 血漿濃度 ,  用量 ,  イマチニブ ,  標準 ,  遵守 ,  慢性骨髄性白血病 ,  患者 ,  分子 ,  応答